Patterns of care in the initial management of women with ovarian cancer in Ontario

Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature

An investigation of patients’ motivations for their participation in genetics-related research

An investigation of patients’ motivations for their participation in genetics-related research

abstract - multinational study: Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers

Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers - abstract - multinational study

Ovarian carcinoma apparently confined to the ovaries--the accuracy of surgical staging in Israel

High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.

Hereditary breast and ovarian cancer: referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the

open access: Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management

Subjects carrying a mutation in one of the MMR genes have a higher risk for developing colorectal cancer, but also for endometrial carcinoma and malignancies of the stomach, small bowel, ovaries, upper uroepithelial tract, biliary tract, skin and brain.(pancreas)

Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008

More importantly, tumour type and stage of disease are essential for drawing conclusions from such findings.

Carey et al.

2008 244 advanced ovarian cancer EORTC QLQ-C30 Performance status and global QOL scores at baseline were prognostic factors for both progression-free survival and overall survival.

Gupta et al.

2008 90 ovarian cancer Ferrans and Powers QLI No statistically significant prognostic
association of patient satisfaction with QOL was observed with survival.